Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : Leucettinib-21
Catalog No.: PC-21506Not For Human Use, Lab Use Only.
Leucettinib-21 is a potent, selective DYRKs and CLKs kinases with IC50 of 2.4, 6.7, 12, 33, and 5 nM for DYRK1A, DYRK1B, CLK1, CLK2, and CLK4, respectively.
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Leucettinib-21 is a potent, selective DYRKs and CLKs kinases with IC50 of 2.4, 6.7, 12, 33, and 5 nM for DYRK1A, DYRK1B, CLK1, CLK2, and CLK4, respectively.
Leucettinib-21 weakly inhibits DYRK2/3/4, and CLK3 (IC50=200-1000 nM), inhibits only weakly inhibits some kinases (RPS6KA4, CDK7, DMPK) in a panel of 468 kinases at 1 uM.
Leucettinib-21 shows Kd values of 0.272 and 0.388 nM for DYRK1A and CLK1, respectively, 26 and 22 times lower than that for Leucettine L41 (Cat#PC-61025).
Leucettinib-21 triggers a dose-dependent inhibition of endogenous DYRK1A catalytic activity in HT-22 mouse hippocampal neuronal cells with IC50 of 36 nM.
Leucettinib-21 (0-10 uM) inhibits the phosphorylation of reported DYRK1A substrate sites in SH-SY5Y cells, such as Thr286-cyclin D1 and Thr212-Tau, protects cyclin D1 from proteolytic degradation, leading to its accumulation.
Leucettinib-21 (0.4 mg/kg, oral gavage daily, 10 days) corrects memory disorders in the Down syndrome mouse model Ts65Dn, a classical animal model of Down syndrome (DS).
| M.Wt | 358.46 | |
| Formula | C18H22N4O2S | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
1. Mattias F. Lindberg, et al. Journal of Medicinal Chemistry, 2023.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
